Connect with us

Fertility

HealthPlus Fertility: first in the UAE to offer Future Fertility’s AI-powered oocyte assessment tech

Unlike the traditional approach to estimating egg quality, Future Fertility’s software considers individual variability

Published

on

HealthPlus Fertility, a prominent fertility clinic network in the United Arab Emirates, is proud to announce its strategic partnership with Future Fertility, the global leader in clinically validated AI-powered fertility solutions.

This partnership marks a significant milestone in the UAE’s fertility landscape, making HealthPlus Fertility the first network of clinics in the region to offer Future Fertility’s personalised oocyte quality reports to its patients.

Services will be available at the clinics in Dubai and Abu Dhabi from October 2023.

Future Fertility’s software leverages artificial intelligence (AI) to analyse oocyte images and provide insight into the reproductive potential of each egg.

Unlike the traditional approach to estimating egg quality, which relies on a patient’s age group and the number of mature eggs retrieved, Future Fertility‘s software considers individual variability. This valuable information empowers patients to make more informed decisions along the fertility journey and enables providers to better optimize treatment plans.

VIOLET, for egg freezing patients, and MAGENTA, for IVF-ICSI patients, are already in use in more than 15 countries, revolutionising the way fertility specialists and embryologists assess egg quality.

HealthPlus Fertility, known for its commitment to excellence in reproductive healthcare, views this partnership as a significant value proposition for its patients.

“At HealthPlus Fertility, we are dedicated to offering the latest advancements in fertility care. Partnering with Future Fertility allows us to deliver tailored insights that enhance patient experiences and have the potential to improve outcomes,” says Jules McDonald, director of clinical operations at HealthPlus Fertility.

Future Fertility’s CEO Christy Prada expressed excitement about increasing access to this technology and partnering with HealthPlus to bring such services to the region.

“We are thrilled that our oocyte quality reports are now available to fertility patients in the UAE. Our goal has always been to empower patients and their providers with personalised insights, enabling them to make informed decisions.

“We couldn’t be more pleased to partner with a highly distinguished and accredited network like HealthPlus, who are renowned for their impressive commitment to quality and patient care.”

Dr Walid Sayed, consultant reproductive endocrinology and infertility and medical director at HealthPlus Fertility, also highlighted the scientific advantages of Future Fertility’s tools, noting: “Until now, embryologists faced challenges in scoring oocyte quality manually, as there has been no validated, agreed-upon oocyte scoring system.

“Future Fertility’s technology bridges this gap, providing a consistent and objective approach to assessing oocyte quality.”

This collaboration comes at a time when the IVF and egg freezing market in the UAE is experiencing remarkable growth.

According to market research, the UAE IVF market is projected to expand at a compound annual growth rate of around 14.12 per cent from 2022 to 2027. This growth is driven by various factors, including an increase in infertility cases and the rising popularity of IVF treatments.

Additionally, the government’s support and changing cultural attitudes have fuelled demand for fertility treatments. Notably, legislation changes in 2021 allowed patients to undergo egg freezing for both medical and social reasons.

The new regulation also allowed human embryos to be frozen for up to five years.

HealthPlus Fertility and Future Fertility are excited to embark on this new partnership and look forward to collaborating on scientific studies that explore novel applications for AI technology and its role in enhancing fertility treatments in the UAE.

Together, they aim to bring innovative and cutting-edge solutions to patients, empowering them on their fertility journey.

Fertility

Paracetamol use may impact future fertility, studies suggest

Published

on

Paracetamol use in pregnancy was not linked to autism or ADHD, while separate research found reproductive differences in girls exposed before birth.

One study analysed health records from more than 120,000 children and found no increased risk of autism following prenatal paracetamol exposure.

A separate analysis of nearly 100,000 children also found no increased risk of ADHD among those born to mothers who used the painkiller during pregnancy.

Researchers from the Hong Kong Hospital Authority examined electronic health records covering pregnancies between January 2001 and December 2023.

The autism analysis included 124,333 children, who were nine years old on average and split almost evenly between males and females. There were 3,445 autism diagnoses, representing 2.8 per cent of the group.

The ADHD analysis involved 97,285 children, who were seven years old on average and also split evenly between males and females. There were 5,168 ADHD diagnoses, representing 5.3 per cent.

Women prescribed paracetamol during pregnancy were more likely to be older and have pre-existing conditions including psychiatric disorders, as well as reasons for taking the drug such as infection, fever or chronic pain.

No association was found between prenatal paracetamol exposure and either autism or ADHD.

The findings did not differ according to the trimester in which paracetamol was taken or whether use was intermittent or daily. Advanced maternal age, defined as pregnancy in women over 35, did not alter the findings.

The researchers wrote: “Paracetamol remains a safe and essential analgesic [pain reliever] and antipyretic [fever reducer] during pregnancy, whereas alternatives, such as NSAIDs and opioids carry well-documented risks.

“Unwarranted reluctance to use paracetamol could lead to undertreatment of pain and fever, or the use of more harmful alternatives, both posing risks to the pregnancy and developing fetus.”

The authors said women should assess paracetamol use with guidance from their doctor.

A separate study involving 685 pregnant women without pre-existing conditions and 302 infant daughters found associations between prenatal paracetamol exposure and differences in reproductive organs and hormone levels.

Researchers from Copenhagen University Hospital enrolled the women during their first trimester and assessed them during the first trimester, third trimester and again when their babies were three months old.

At around three months, infants experience a temporary rise in reproductive hormones sometimes called mini-puberty.

Pregnant participants completed questionnaires every two weeks about their use of pain medicines including paracetamol. Infant girls underwent ultrasound scans of their reproductive organs and blood tests to measure hormone levels.

Researchers also examined a separate group of 1,210 girls followed from infancy to adolescence whose mothers reported paracetamol use during the third trimester.

Three-month-old girls exposed to paracetamol before birth had an average 40 per cent smaller ovarian volume, 13 per cent smaller uterine volume and 23 per cent fewer ovarian follicles.

Girls exposed during the first trimester also had lower levels of Anti-Müllerian hormone, a marker of ovarian function.

Among the older girls, those exposed before birth were more likely to have smaller uteruses at puberty and smaller ovaries during their teenage years.

Dr Margit Bistrup Fischer, lead study author and postdoctoral researcher in the Department of Growth and Reproduction at Rigshospitalet hospital in Denmark, said: “Animal studies have demonstrated that impaired formation of ovarian follicles can lead to reduced fertility and earlier reproductive aging.

“Whether the differences observed in our study have implications for fertility and age at menopause in humans remains unknown and will require long-term follow-up of the girls in our cohort.”

She cautioned that women who had used paracetamol during pregnancy “should not be alarmed by our findings”, as the study found associations rather than direct causation and outcomes for individual women and children are unclear.

“Importantly, our study does not evaluate whether [acetaminophen] causes reproductive problems, nor does it provide evidence that prenatal exposure affects future fertility or age at menopause,” she said.

“Although we observed similar associations in an independent cohort, long-term follow-up is needed to determine whether these early-life differences have any clinical significance later in life.”

Continue Reading

Insight

Fertility rate in England and Wales hits record low, new figures reveal

Published

on

The fertility rate in England and Wales fell to a record low of 1.39 children per woman in 2025, down from 1.41 a year earlier.

New figures show that parts of London and cities with major universities accounted for many of the areas with the lowest local fertility rates.

The City of London recorded the lowest rate in 2025 at 0.37 children per woman, followed by Cambridge at 0.87 and the London boroughs of Islington and Westminster at 0.90.

The Office for National Statistics (ONS) defines the fertility rate as the average number of live children women would expect to have over their childbearing lives.

Brighton & Hove recorded a rate of 0.95, followed by Southwark at 0.97 and Norwich at 0.98.

Exeter, Oxford and York, along with the London boroughs of Camden and Hammersmith & Fulham, each recorded 1.01 children per woman.

At the other end of the table, Pendle in Lancashire and Luton in Bedfordshire had the highest rate at 1.93.

They were followed by Oldham in Greater Manchester at 1.87, Bradford in West Yorkshire at 1.84 and Barking & Dagenham in London at 1.83.

The overall fertility rate for England and Wales declined from 1.41 in 2024 to 1.39 in 2025.

A rate of around 2.1 is needed for a population to remain stable over time when the impact of migration is excluded.

Twelve of the 25 local authorities with the lowest fertility rates in 2025 were in London.

In Wales, Swansea recorded the lowest fertility rate at 1.18, while Carmarthenshire, the Isle of Anglesey and Newport each had the highest rate at 1.48.

There were 585,396 live births in England and Wales in 2025, down from 594,677 in 2024 and the lowest number since 1977.

Live births fell across every region in England. The West Midlands recorded the largest percentage decline at 3.1 per cent, while the North East had the smallest at 0.3 per cent.

The average age of parents also increased slightly.

Mothers had a provisional standardised mean age of 31.1 in 2025, compared with 31.0 in 2024. Fathers had an average age of 34.0, up from 33.9.

In 1975, the average age was 26.4 for mothers and 29.5 for fathers.

The proportion of births where the mother was born outside the UK also increased, from 20.8 per cent in 2005 to 27.5 per cent in 2015 and 34.6 per cent in 2025.

India was the most common country of birth for non-UK-born mothers in 2025 for the fourth consecutive year.

It was followed by Pakistan, Nigeria and Romania.

In 2025, 56.4 per cent of births were to parents who were both born in the UK, down from 62.7 per cent in 2015.

Continue Reading

Fertility

Weight loss surgery improves menstrual health and PMOS symptoms, study finds

Published

on

Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.

The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.

Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.

Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.

Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.

Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.

Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.

Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.

Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.

“So much remains unknown about the impact of this type of surgery on women who are planning to have children.

“This raises the question of when the ideal time after surgery is to conceive.”

Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.

The researchers said 17 women had healthy pregnancies following surgery.

Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.

Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.

“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.

“By reducing this, what we have seen is that it can lead to improvements without the need for medication.

“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.